Algorae to Evaluate 24 New Drug Targets Predicted by the AlgoraeOS Artificial Intelligence Drug Discovery Platform

Highlights:

- Algorae identifies 24 wholly owned AI-generated drug targets to evaluate in preclinical studies, majorly expanding the Company's therapeutic pipeline.
- New drug targets were generated by Version 1 of Algorae Operating System developed in conjunction with UNSW AI Institute, with grant funding support from CSIRO.
- Development of Version 2 of AlgoraeOS underway to expand pharmaceutical databases, enhance AI models, increasing predictive capacity in additional fields of medicine.
- New drug targets show promise in a range of oncology medical indications, representing health markets with significant unmet need.

Melbourne, Australia – 21 November 2024: Algorae Pharmaceuticals ('Algorae' or the 'Company') (ASX: 1AI), an artificial intelligence ('AI') enabled drug discovery and development company today announces that it has finalised its initial catalogue of AI-generated drug targets that will proceed to preclinical studies.

Version 1 of Algorae Operating System ('AlgoraeOS') was launched on 24 September 2024 and the AI-enabled platform has generated 46 drug targets. Following analysis of commercial and intellectual property potentiality, Algorae intends to undertake preclinical studies in twenty-four [24] wholly owned new drug targets. Discussions with an Australian-based pharmaceutical drug laboratory are underway to complete these studies in a timely and cost-effective manner.

The new drug targets are applicable to a range of oncology medical indications with significant unmet need, including breast cancer, lung cancer, leukemia and glioblastoma, among others. Results from the *in vitro* preclinical assessments for each target will verify efficacy and safety, which, if successful, will de-risk further development internally or in partnership with other pharmaceutical companies.

Executive Chairman of Algorae, Mr David Hainsworth said, "AlgoraeOS is the only platform of its kind in Australia and today we're excited to reveal that we've successfully used the platform to expand our therapeutic pipeline by 24 promising new targets. This significant expansion highlights the important competitive advantage of AI to predict new therapeutic entities ahead of our competitors relying on conventional approaches. Targets that show promise in laboratory studies will either be developed internally or earmarked for potential development with a partner".

About AlgoraeOS

AlgoraeOS is the Company's proprietary artificial intelligence biopharmaceutical prediction platform being developed in collaboration with AI experts from the University of New South Wales ('UNSW') and supported by co-funding from the CSIRO Next Generation AI Graduate Program. AlgoraeOS is designed to predict synergistic fixed dose combination drug targets using machine learning, deep learning, and neural network

Algorae Pharmaceuticals Limited [ABN: 14 104 028 042]
Level 23, Rialto South Tower, 525 Collins St, Melbourne VIC 3000
P: +61 422 180 317

1

algorithms within the setting of a vast compilation of medical and scientific data curated for the purpose of AI-enabled combination drug discovery.

AlgoraeOS is hosted by the 'Gadi' supercomputer operated by National Computational Infrastructure (NCI Australia) and previously used for the likes of climate modelling and natural disaster prediction. The supercomputer has peak operational capacity of over 10 petaFLOPS, which exceeds the computational capacity of many other AI-enabled biopharmaceutical prediction platforms.

This announcement has been approved by the Board of Directors of Algorae Pharmaceuticals Limited.

End

For more information, please visit www.algoraepharma.com

Corporate and Media Enquiries
Mr Brad Dilkes - Director
P: +61 422 180 317
E: brad@algoraepharma.com

About Algorae Pharmaceuticals

Algorae is a pharmaceutical development company focussed on addressing unmet medical needs through the discovery and development of novel treatments. The Company has assembled a proficient R&D team and established collaborations with reputable academic institutions to advance its promising drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, AI-168 for cardiovascular disease and NTCELL for Parkinson's disease.

Algorae intends to expand its therapeutic pipeline using a proprietary artificial intelligence drug discovery and development platform. Known as Algorae Operating System ('AlgoraeOS'), the AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the aim of AlgoraeOS is to uncover synergistic drug combinations that lead to the development of novel and effective treatments for any medical condition, aligning with Algorae's commitment to address unmet medical needs. Algorae is listed and publicly traded on the Australian Stock Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Algorae Pharmaceuticals Limited [ABN: 14 104 028 042]
Level 23, Rialto South Tower, 525 Collins St, Melbourne VIC 3000
P: +61 422 180 317

2